Teradyne,
Inc. (NYSE: TER) reported revenue of $262 million for the third
quarter of 2009. Semiconductor Test revenue totaled $173 million and
Systems Test Group revenue totaled $89 million. On a non-GAAP basis,
Teradyne’s income from continuing operations in the third quarter was
$24.8 million, or $0.14 per diluted share, which excluded restructuring
charges, acquired intangible asset amortization and special items. GAAP
income from continuing operations for the third quarter was $6.7
million, or $0.04 per diluted share.
Bookings in the third quarter of 2009 were $288 million of which $233
million was in Semiconductor Test and $55 million in Systems Test Group.
Guidance for the fourth quarter of 2009 is for revenue of $255 million
to $270 million, with Non-GAAP net income per share of $0.12 to $0.17
and GAAP net income per share between $0.04 and $0.09. Non-GAAP guidance
excludes restructuring charges, acquired intangible asset amortization
and special items.
"Our Semiconductor and Systems Test businesses continued to gain
strength through the quarter driving our return to operating
profitability and positive outlook for Q4,” said Teradyne President and
CEO Mike Bradley. "We reached a major milestone in our expansion into
new markets as we received initial orders for the UltraFLEX-M high-speed
memory test system.”
Webcast
A webcast to discuss third quarter 2009 results, along with management's
business outlook will be held at 10 a.m. EDT, Thursday, October 29.
Interested investors should access the webcast at www.teradyne.com
and click on "Investors" at least five minutes before the call begins.
The webcast replay will be available on www.teradyne.com.
In addition, a conference call replay will be available approximately
two hours after the call. The replay number in the U.S. & Canada is
800-642-1687. The replay number outside the U.S. & Canada is
706-645-9291. The pass code for both numbers is 36016837. The replay
will be available via phone and web site through November 13, 2009.
Non-GAAP Results
In addition to disclosing results that are determined in accordance with
GAAP, Teradyne also discloses non-GAAP results of operations that
exclude certain income items and charges. These results are provided as
a complement to results provided in accordance with GAAP. Teradyne
reports non-GAAP results in order to better assess and reflect operating
performance. Management believes the non-GAAP measures help indicate
Teradyne's baseline performance before gains, losses or other charges
that may not be indicative of our current core business or future
outlook. Teradyne believes these non-GAAP measures will aid investors'
overall understanding of its results by providing a higher degree of
transparency for certain expenses and providing a level of disclosure
that will help investors understand how Teradyne plans and measures its
own business. A reconciliation of each available GAAP to non-GAAP
financial measure discussed in this press release is contained in the
attached exhibits and on the Teradyne website at www.teradyne.com
by clicking on "Investors" and then selecting the "GAAP to Non-GAAP
Reconciliation" link. The presentation of non-GAAP measures is not meant
to be considered in isolation, as a substitute for, or superior to,
financial measures or information provided in accordance with GAAP.
About Teradyne
Teradyne (NYSE:TER) is a leading supplier of Automatic Test Equipment
used to test complex electronics used in the consumer electronics,
automotive, computing, telecommunications, and aerospace and defense
industries. In 2008, Teradyne had sales of $1.1 billion. For more
information, visit www.teradyne.com.
Teradyne(R) is a registered trademark of Teradyne, Inc. in the U.S. and
other countries. All product names are trademarks of Teradyne, Inc.
(including its subsidiaries) or their respective owners.
Safe Harbor Statement
The forward-looking statements included in this release are made only as
of the date of publication. Teradyne disclaims any intention or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.
This release contains forward-looking statements regarding future
business prospects, Teradyne’s results of operations and market
conditions. Such statements are based on the current assumptions and
expectations of Teradyne’s management and are neither promises nor
guarantees of future performance. You can identify these forward-looking
statements based on the context of the statements and by the fact that
they use words such as "will,” "anticipate,” "expect,” "project,”
"intend,” "plan,” "believe,” "target” and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance. There can be no assurance that management’s
estimates of Teradyne’s future results or other forward looking
statements will be achieved. Important factors that could cause actual
results to differ materially from those presently expected include:
conditions affecting the markets in which Teradyne operates; decreased
product demand; delays in new product introductions; lack of customer
acceptance of new products; unanticipated delays in or costs and
expenses relating to the implementation of cost reduction plans; and
other events, factors and risks disclosed in filings with the SEC,
including, but not limited to, the "Risk Factors” section of Teradyne’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2008
and Quarterly Report on Form 10-Q for the period ended July 5, 2009. The
forward-looking statements provided by Teradyne in this press release
represent management’s views as of the date of this release. Teradyne
anticipates that subsequent events and developments may cause
management's views to change. However, while Teradyne may elect to
update these forward-looking statements at some point in the future,
Teradyne specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing
Teradyne's views as of any date subsequent to the date of this release.
|
TERADYNE, INC. REPORT FOR THIRD FISCAL QUARTER OF 2009
|
|
|
|
CONDENSED CONSOLIDATED OPERATING STATEMENTS
|
|
(In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended:
|
|
|
Nine Months Ended:
|
|
|
|
|
|
October 4, 2009
|
|
July 5, 2009
|
|
September 28, 2008
|
|
|
October 4, 2009
|
|
September 28, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues
|
|
$
|
262,162
|
|
|
$
|
169,580
|
|
|
$
|
297,255
|
|
|
|
$
|
552,350
|
|
|
$
|
912,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Revenues (1)
|
|
|
155,407
|
|
|
|
122,451
|
|
|
|
169,325
|
|
|
|
|
365,106
|
|
|
|
491,994
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
|
|
106,755
|
|
|
|
47,129
|
|
|
|
127,930
|
|
|
|
|
187,244
|
|
|
|
420,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineering and Development
|
|
|
38,266
|
|
|
|
38,451
|
|
|
|
52,969
|
|
|
|
|
123,915
|
|
|
|
164,272
|
|
|
|
Selling and Administrative
|
|
|
46,314
|
|
|
|
47,257
|
|
|
|
58,614
|
|
|
|
|
148,944
|
|
|
|
189,298
|
|
|
|
Acquired Intangible Asset Amortization
|
|
|
8,214
|
|
|
|
8,214
|
|
|
|
5,034
|
|
|
|
|
24,667
|
|
|
|
13,671
|
|
|
|
In-process Research and Development
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
1,100
|
|
|
|
Restructuring and Other, net (2)
|
|
|
5,189
|
|
|
|
15,270
|
|
|
|
28,589
|
|
|
|
|
36,424
|
|
|
|
53,100
|
|
|
|
|
Operating Expenses
|
|
|
97,983
|
|
|
|
109,192
|
|
|
|
145,206
|
|
|
|
|
333,950
|
|
|
|
421,441
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(Loss) from Operations
|
|
|
8,772
|
|
|
|
(62,063
|
)
|
|
|
(17,276
|
)
|
|
|
|
(146,706
|
)
|
|
|
(1,160
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest & Other (3)
|
|
|
(3,597
|
)
|
|
|
(6,905
|
)
|
|
|
(3,111
|
)
|
|
|
|
(15,555
|
)
|
|
|
4,419
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(Loss) from Continuing Operations Before Income Taxes
|
|
|
5,175
|
|
|
|
(68,968
|
)
|
|
|
(20,387
|
)
|
|
|
|
(162,261
|
)
|
|
|
3,259
|
|
|
|
Income Tax (Benefit)/Provision
|
|
|
(1,500
|
)
|
|
|
(2,200
|
)
|
|
|
3,070
|
|
|
|
|
(11,500
|
)
|
|
|
13,270
|
|
|
Income/(Loss) from Continuing Operations
|
|
|
6,675
|
|
|
|
(66,768
|
)
|
|
|
(23,457
|
)
|
|
|
|
(150,761
|
)
|
|
|
(10,011
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Discontinued Operations Before Income Taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
768
|
|
|
|
|
-
|
|
|
|
768
|
|
|
|
Income Tax (Benefit)/Provision
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
-
|
|
|
Income from Discontinued Operations
|
|
|
-
|
|
|
|
-
|
|
|
|
768
|
|
|
|
|
-
|
|
|
|
768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income/(Loss)
|
|
$
|
6,675
|
|
|
$
|
(66,768
|
)
|
|
$
|
(22,689
|
)
|
|
|
$
|
(150,761
|
)
|
|
$
|
(9,243
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(Loss) per Common Share from
Continuing Operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.04
|
|
|
$
|
(0.39
|
)
|
|
$
|
(0.14
|
)
|
|
|
$
|
(0.87
|
)
|
|
$
|
(0.06
|
)
|
|
Diluted
|
|
$
|
0.04
|
|
|
$
|
(0.39
|
)
|
|
$
|
(0.14
|
)
|
|
|
$
|
(0.87
|
)
|
|
$
|
(0.06
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income/(Loss) per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.04
|
|
|
$
|
(0.39
|
)
|
|
$
|
(0.13
|
)
|
|
|
$
|
(0.87
|
)
|
|
$
|
(0.05
|
)
|
|
Diluted
|
|
$
|
0.04
|
|
|
$
|
(0.39
|
)
|
|
$
|
(0.13
|
)
|
|
|
$
|
(0.87
|
)
|
|
$
|
(0.05
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares - Basic
|
|
|
174,495
|
|
|
|
173,022
|
|
|
|
168,769
|
|
|
|
|
173,216
|
|
|
|
171,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares - Diluted
|
|
|
180,792
|
|
|
|
173,022
|
|
|
|
168,769
|
|
|
|
|
173,216
|
|
|
|
171,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Orders
|
|
$
|
288,048
|
|
|
$
|
227,331
|
|
|
$
|
198,072
|
|
|
|
$
|
651,725
|
|
|
$
|
827,067
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Cost of Revenues includes:
|
|
Quarter Ended:
|
|
|
Nine Months Ended:
|
|
|
|
|
|
October 4, 2009
|
|
July 5, 2009
|
|
September 28, 2008
|
|
|
October 4, 2009
|
|
September 28, 2008
|
|
|
|
Provision for Excess and Obsolete Inventory
|
|
$
|
6,915
|
|
|
$
|
11,491
|
|
|
$
|
21,715
|
|
|
|
$
|
27,003
|
|
|
$
|
24,969
|
|
|
|
|
Cost for Purchase Accounting Inventory Step-up
|
|
|
5,700
|
|
|
|
3,924
|
|
|
|
-
|
|
|
|
|
10,863
|
|
|
|
4,346
|
|
|
|
|
Sale of Previously Written Down Inventory
|
|
|
(588
|
)
|
|
|
-
|
|
|
|
(528
|
)
|
|
|
|
(588
|
)
|
|
|
(1,442
|
)
|
|
|
|
Insurance Recovery Gain
|
|
|
-
|
|
|
|
(1,000
|
)
|
|
|
-
|
|
|
|
|
(1,000
|
)
|
|
|
-
|
|
|
|
|
|
|
$
|
12,027
|
|
|
$
|
14,415
|
|
|
$
|
21,187
|
|
|
|
$
|
36,278
|
|
|
$
|
27,873
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Restructuring and other, net consists of:
|
|
Quarter Ended:
|
|
|
Nine Months Ended:
|
|
|
|
|
|
October 4, 2009
|
|
July 5, 2009
|
|
September 28, 2008
|
|
|
October 4, 2009
|
|
September 28, 2008
|
|
|
|
Facility Related
|
|
$
|
4,419
|
|
|
$
|
-
|
|
|
$
|
3,404
|
|
|
|
$
|
4,419
|
|
|
$
|
16,424
|
|
|
|
|
Employee Severance
|
|
|
1,237
|
|
|
|
14,976
|
|
|
|
2,620
|
|
|
|
|
32,891
|
|
|
|
15,243
|
|
|
|
|
Eagle Test Purchase Accounting Adjustment & Other
|
|
|
(467
|
)
|
|
|
(774
|
)
|
|
|
-
|
|
|
|
|
(1,954
|
)
|
|
|
-
|
|
|
|
|
Long-Lived Asset Impairment
|
|
|
-
|
|
|
|
1,068
|
|
|
|
-
|
|
|
|
|
1,068
|
|
|
|
550
|
|
|
|
|
Loss on Sale of Real Estate
|
|
|
-
|
|
|
|
-
|
|
|
|
22,565
|
|
|
|
|
-
|
|
|
|
20,883
|
|
|
|
|
|
|
$
|
5,189
|
|
|
$
|
15,270
|
|
|
$
|
28,589
|
|
|
|
$
|
36,424
|
|
|
$
|
53,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Interest and Other includes:
|
|
Quarter Ended:
|
|
|
Nine Months Ended:
|
|
|
|
|
|
October 4, 2009
|
|
July 5, 2009
|
|
September 28, 2008
|
|
|
October 4, 2009
|
|
September 28, 2008
|
|
|
|
Amortization of GAAP Imputed Convertible Debt Discount
|
|
$
|
2,329
|
|
|
$
|
2,251
|
|
|
$
|
-
|
|
|
|
$
|
4,580
|
|
|
$
|
-
|
|
|
|
|
Expense for Deferred Debt Financing Costs as a Result of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment and Termination of the Revolving Line of Credit
|
|
|
-
|
|
|
|
2,488
|
|
|
|
-
|
|
|
|
|
2,488
|
|
|
|
-
|
|
|
|
|
Other-Than-Temporary Impairment and Realized
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gains)/Losses on Marketable Securities
|
|
|
(572
|
)
|
|
|
-
|
|
|
|
8,437
|
|
|
|
|
2,000
|
|
|
|
8,437
|
|
|
|
|
Gain on Sale of an Equity Investment
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,811
|
)
|
|
|
|
-
|
|
|
|
(2,811
|
)
|
|
|
|
Gain on Life Insurance
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,352
|
)
|
|
|
|
-
|
|
|
|
(1,352
|
)
|
|
|
|
Charge for Acquisition Financing Fees
|
|
|
-
|
|
|
|
-
|
|
|
|
1,227
|
|
|
|
|
-
|
|
|
|
1,227
|
|
|
|
|
|
|
$
|
1,757
|
|
|
$
|
4,739
|
|
|
$
|
5,501
|
|
|
|
$
|
9,068
|
|
|
$
|
5,501
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)
|
|
|
|
|
October 4, 2009
|
|
December 31, 2008
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
Cash and Cash Equivalents
|
|
$
|
406,741
|
|
$
|
322,705
|
|
|
Marketable Securities
|
|
|
5,735
|
|
|
-
|
|
|
Accounts Receivable
|
|
|
139,693
|
|
|
109,625
|
|
|
Inventories (1)
|
|
|
111,970
|
|
|
168,451
|
|
|
Deferred Tax Assets
|
|
|
17,561
|
|
|
16,988
|
|
|
Prepayments and Other Current Assets
|
|
|
60,348
|
|
|
60,884
|
|
|
|
|
|
742,048
|
|
|
678,653
|
|
|
|
|
|
|
|
|
|
Net Property, Plant and Equipment
|
|
|
250,151
|
|
|
298,449
|
|
|
Long-Term Marketable Securities
|
|
|
55,033
|
|
|
51,613
|
|
|
Intangible Assets
|
|
|
160,592
|
|
|
186,998
|
|
|
Other Assets
|
|
|
18,669
|
|
|
19,534
|
|
|
|
|
$
|
1,226,493
|
|
$
|
1,235,247
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
Accounts Payable
|
|
|
70,613
|
|
|
61,164
|
|
|
Current Debt (2)
|
|
|
2,237
|
|
|
122,500
|
|
|
Accrued Employees' Compensation and Withholdings
|
|
|
52,053
|
|
|
73,521
|
|
|
Deferred Revenue and Customer Advances
|
|
|
127,993
|
|
|
58,030
|
|
|
Other Accrued Liabilities
|
|
|
50,184
|
|
|
51,748
|
|
|
|
|
|
303,080
|
|
|
366,963
|
|
|
|
|
|
|
|
|
|
Retirement Plans Liabilities
|
|
|
134,465
|
|
|
125,877
|
|
|
Deferred Tax Liabilities
|
|
|
3,045
|
|
|
8,730
|
|
|
Other Long-Term Liabilities
|
|
|
23,623
|
|
|
27,565
|
|
|
Long-Term Debt (2) (3)
|
|
|
138,970
|
|
|
-
|
|
|
|
|
|
603,183
|
|
|
529,135
|
|
|
|
|
|
|
|
|
Shareholders' Equity
|
|
|
623,310
|
|
|
706,112
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,226,493
|
|
$
|
1,235,247
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) As of October 4, 2009 and December 31, 2008, Inventories
included approximately $4.5 million and $15.4 million, respectively,
for Eagle Test inventory fair value step-up.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) On March 31, 2009, we entered into a loan agreement in Japan
for approximately $10 million. The loan has a term of 5 years and
a fixed interest rate of 1.4%. At October 4, 2009, $2.2 million of
the outstanding loan principal is included in current debt and
$7.8 million is classified as long-term debt.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) On March 31, 2009, in connection with our convertible note
offering, we entered into convertible note hedge and warrant
transactions. These transactions are expected to reduce the
potential dilution to Teradyne's common stock upon maturity of the
convertible notes. On April 6, 2009, the convertible note and
convertible note hedge and warrant transactions closed and we netted
approximately $163 million of cash, before paying off the $122.5
million bank revolver.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For information on possible dilution related to the convertible
note, investors should access Teradyne's website at www.teradyne.com
and click on "Investors" and then select the "Financial Data" link.
|
|
GAAP to Non-GAAP Earnings Reconciliation
|
|
|
|
References by the Company to non-GAAP income/(loss) and non-GAAP
income/(loss) per share refer to income/(loss) from continuing
operations or income/(loss) per common share from continuing
operations excluding goodwill impairment, in-process research and
development, amortization of the GAAP imputed convertible debt
discount, write-off of credit line debt issue costs, restructuring
and other, net, certain inventory provision reversals, fair value
inventory step-up related to Nextest and Eagle Test,
(losses)/gains on marketable securities and acquired intangible
asset amortization, as well as applicable adjustments to profit
sharing and income taxes due to these exclusions. GAAP requires
that these items be included in determining income/(loss) from
continuing operations. Non-GAAP income/(loss) from continuing
operations (which is the basis for non-GAAP income/(loss) from
continuing operations per share) gives an indication of Teradyne's
baseline performance before gains, losses or other charges that
may not be indicative of our current core business or future
outlook.
|
|
|
|
The Company believes these non-GAAP measures will aid investors'
overall understanding of the Company's results by providing a higher
degree of transparency for certain expenses and providing a level of
disclosure that will help investors understand how the Company plans
and measures its own business. However, the presentation of non-GAAP
measures is not meant to be considered in isolation or as a
substitute for, or superior to, financial information provided in
accordance with GAAP.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions, except per share amounts)
|
|
|
|
|
|
Quarter Ended:
|
|
|
|
|
Nine Months Ended:
|
|
|
|
|
|
|
|
October 4, 2009
|
|
|
|
July 5, 2009
|
|
|
|
September 28, 2008
|
|
|
|
|
October 4, 2009
|
|
|
|
September 28, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues
|
|
$
|
262.2
|
|
|
|
|
$
|
169.6
|
|
|
|
|
$
|
297.3
|
|
|
|
|
|
$
|
552.4
|
|
|
|
|
$
|
912.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Margin - GAAP
|
|
$
|
106.8
|
|
|
40.7
|
%
|
|
$
|
47.1
|
|
|
27.8
|
%
|
|
$
|
127.9
|
|
|
43.0
|
%
|
|
|
$
|
187.2
|
|
|
33.9
|
%
|
|
$
|
420.3
|
|
|
46.1
|
%
|
|
|
Inventory step-up reversal (1)
|
|
|
5.7
|
|
|
|
|
|
3.9
|
|
|
|
|
|
-
|
|
|
|
|
|
|
10.9
|
|
|
|
|
|
4.3
|
|
|
|
|
|
Insurance recovery
|
|
|
-
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
Inventory provision reversal (2)
|
|
|
(0.6
|
)
|
|
|
|
|
-
|
|
|
|
|
|
(0.5
|
)
|
|
|
|
|
|
(0.6
|
)
|
|
|
|
|
(1.4
|
)
|
|
|
|
|
Profit sharing adjustment (3)
|
|
|
(0.4
|
)
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
(0.4
|
)
|
|
|
|
|
(0.3
|
)
|
|
|
|
Gross Margin - non-GAAP
|
|
$
|
111.5
|
|
|
42.5
|
%
|
|
$
|
50.0
|
|
|
29.5
|
%
|
|
$
|
127.4
|
|
|
42.9
|
%
|
|
|
$
|
196.1
|
|
|
35.5
|
%
|
|
$
|
422.9
|
|
|
46.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(Loss) from Operations - GAAP
|
|
$
|
8.8
|
|
|
3.4
|
%
|
|
$
|
(62.1
|
)
|
|
-36.6
|
%
|
|
$
|
(17.3
|
)
|
|
-5.8
|
%
|
|
|
$
|
(146.7
|
)
|
|
-26.6
|
%
|
|
$
|
(1.2
|
)
|
|
-0.1
|
%
|
|
|
Acquired intangible asset amortization
|
|
|
8.2
|
|
|
|
|
|
8.2
|
|
|
|
|
|
5.0
|
|
|
|
|
|
|
24.7
|
|
|
|
|
|
13.7
|
|
|
|
|
|
Inventory step-up reversal (1)
|
|
|
5.7
|
|
|
|
|
|
3.9
|
|
|
|
|
|
-
|
|
|
|
|
|
|
10.9
|
|
|
|
|
|
4.3
|
|
|
|
|
|
Restructuring and other, net (4)
|
|
|
5.2
|
|
|
|
|
|
15.3
|
|
|
|
|
|
28.6
|
|
|
|
|
|
|
36.4
|
|
|
|
|
|
53.1
|
|
|
|
|
|
Inventory provision reversal (2)
|
|
|
(0.6
|
)
|
|
|
|
|
-
|
|
|
|
|
|
(0.5
|
)
|
|
|
|
|
|
(0.6
|
)
|
|
|
|
|
(1.4
|
)
|
|
|
|
|
In-process research and development
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
-
|
|
|
|
|
|
1.1
|
|
|
|
|
|
Insurance recovery
|
|
|
-
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
Profit sharing adjustment (3)
|
|
|
(2.2
|
)
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
(2.2
|
)
|
|
|
|
|
(1.5
|
)
|
|
|
|
Income/(Loss) from Operations - non-GAAP
|
|
$
|
25.1
|
|
|
9.6
|
%
|
|
$
|
(35.7
|
)
|
|
-21.0
|
%
|
|
$
|
15.8
|
|
|
5.3
|
%
|
|
|
$
|
(78.5
|
)
|
|
-14.2
|
%
|
|
$
|
68.1
|
|
|
7.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(Loss) from Continuing Operations - GAAP
|
|
$
|
6.7
|
|
|
2.6
|
%
|
|
$
|
(66.8
|
)
|
|
-39.4
|
%
|
|
$
|
(23.5
|
)
|
|
-7.9
|
%
|
|
|
$
|
(150.8
|
)
|
|
-27.3
|
%
|
|
$
|
(10.0
|
)
|
|
-1.1
|
%
|
|
|
Acquired intangible asset amortization
|
|
|
8.2
|
|
|
|
|
|
8.2
|
|
|
|
|
|
5.0
|
|
|
|
|
|
|
24.7
|
|
|
|
|
|
13.7
|
|
|
|
|
|
Inventory step-up reversal (1)
|
|
|
5.7
|
|
|
|
|
|
3.9
|
|
|
|
|
|
-
|
|
|
|
|
|
|
10.9
|
|
|
|
|
|
4.3
|
|
|
|
|
|
Restructuring and other, net (4)
|
|
|
5.2
|
|
|
|
|
|
15.3
|
|
|
|
|
|
28.6
|
|
|
|
|
|
|
36.4
|
|
|
|
|
|
53.1
|
|
|
|
|
|
Interest and other (5)
|
|
|
1.8
|
|
|
|
|
|
4.7
|
|
|
|
|
|
5.5
|
|
|
|
|
|
|
9.1
|
|
|
|
|
|
5.5
|
|
|
|
|
|
Inventory provision reversal (2)
|
|
|
(0.6
|
)
|
|
|
|
|
-
|
|
|
|
|
|
(0.5
|
)
|
|
|
|
|
|
(0.6
|
)
|
|
|
|
|
(1.4
|
)
|
|
|
|
|
In-process research and development
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
-
|
|
|
|
|
|
1.1
|
|
|
|
|
|
Insurance recovery
|
|
|
-
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
Profit sharing adjustment (3)
|
|
|
(2.2
|
)
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
(2.2
|
)
|
|
|
|
|
(1.5
|
)
|
|
|
|
|
Income tax adjustment (6)
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
|
(2.9
|
)
|
|
|
|
|
0.2
|
|
|
|
|
Income/(Loss) from Continuing Operations - non-GAAP
|
|
$
|
24.8
|
|
|
9.5
|
%
|
|
$
|
(35.7
|
)
|
|
-21.0
|
%
|
|
$
|
15.1
|
|
|
5.1
|
%
|
|
|
$
|
(76.4
|
)
|
|
-13.8
|
%
|
|
$
|
65.0
|
|
|
7.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Income/(Loss) per Common Share from Continuing Operations -
Basic
|
|
$
|
0.04
|
|
|
|
|
$
|
(0.39
|
)
|
|
|
|
$
|
(0.14
|
)
|
|
|
|
|
$
|
(0.87
|
)
|
|
|
|
$
|
(0.06
|
)
|
|
|
|
Non-GAAP Income/(Loss) per Common Share from Continuing Operations -
Basic
|
|
$
|
0.14
|
|
|
|
|
$
|
(0.21
|
)
|
|
|
|
$
|
0.09
|
|
|
|
|
|
$
|
(0.44
|
)
|
|
|
|
$
|
0.38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP and Non-GAAP Weighted Average Common Shares - Basic
|
|
|
174.5
|
|
|
|
|
|
173.0
|
|
|
|
|
|
168.8
|
|
|
|
|
|
|
173.2
|
|
|
|
|
|
171.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Income/(Loss) per Common Share from Continuing Operations -
Diluted
|
|
$
|
0.04
|
|
|
|
|
$
|
(0.39
|
)
|
|
|
|
$
|
(0.14
|
)
|
|
|
|
|
$
|
(0.87
|
)
|
|
|
|
$
|
(0.06
|
)
|
|
|
|
Non-GAAP Income/(Loss) per Common Share from Continuing Operations -
Diluted
|
|
$
|
0.14
|
|
|
|
|
$
|
(0.21
|
)
|
|
|
|
$
|
0.09
|
|
|
|
|
|
$
|
(0.44
|
)
|
|
|
|
$
|
0.37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Weighted Average Common Shares - Diluted
|
|
|
180.8
|
|
|
|
|
|
173.0
|
|
|
|
|
|
168.8
|
|
|
|
|
|
|
173.2
|
|
|
|
|
|
171.1
|
|
|
|
|
Non-GAAP Weighted Average Common Shares - Diluted
|
|
|
179.0
|
|
|
|
|
|
173.0
|
|
|
|
|
|
170.3
|
|
|
|
|
|
|
173.2
|
|
|
|
|
|
173.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Reversal of Nextest and Eagle Test purchase accounting inventory
step-up.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Reversal of previously written down inventory for non-FLEX
products in the Semiconductor Test Division.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Profit sharing adjustment for non-GAAP items.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) Restructuring and other, net consists of (in millions):
|
|
|
|
|
|
Quarter Ended:
|
|
|
|
|
Nine Months Ended:
|
|
|
|
|
|
|
|
October 4, 2009
|
|
|
|
July 5, 2009
|
|
|
|
September 28, 2008
|
|
|
|
|
October 4, 2009
|
|
|
|
September 28, 2008
|
|
|
|
|
|
Facility Related
|
|
$
|
4.4
|
|
|
|
|
$
|
-
|
|
|
|
|
$
|
3.4
|
|
|
|
|
|
$
|
4.4
|
|
|
|
|
$
|
16.4
|
|
|
|
|
|
|
Employee Severance
|
|
|
1.2
|
|
|
|
|
|
15.0
|
|
|
|
|
|
2.6
|
|
|
|
|
|
|
32.9
|
|
|
|
|
|
15.2
|
|
|
|
|
|
|
Eagle Test Purchase Accounting Adjustment & Other
|
|
|
(0.4
|
)
|
|
|
|
|
(0.8
|
)
|
|
|
|
|
-
|
|
|
|
|
|
|
(2.0
|
)
|
|
|
|
|
-
|
|
|
|
|
|
|
Long-Lived Asset Impairment
|
|
|
-
|
|
|
|
|
|
1.1
|
|
|
|
|
|
-
|
|
|
|
|
|
|
1.1
|
|
|
|
|
|
0.6
|
|
|
|
|
|
|
Loss on Sale of Real Estate
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
22.6
|
|
|
|
|
|
|
-
|
|
|
|
|
|
20.9
|
|
|
|
|
|
|
|
|
$
|
5.2
|
|
|
|
|
$
|
15.3
|
|
|
|
|
$
|
28.6
|
|
|
|
|
|
$
|
36.4
|
|
|
|
|
$
|
53.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) For the quarter and nine months ended October 4, 2009,
Interest and Other included amortization of the GAAP imputed
convertible debt discount. For the quarter ended July 5, 2009 and
nine months ended October 4, 2009, Interest and Other included a
charge to expense deferred debt financing costs as a result of the
repayment and termination of Teradyne's revolving line of credit.
For the nine months ended October 4, 2009, Interest and Other
included a charge for other-than-temporary impairment and realized
(losses)/gains on marketable securities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6) Income tax adjustment for non-GAAP items. For the nine months
ended October 4, 2009, the income tax adjustment related to a
discrete foreign exchange item.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For press releases and other information of interest to investors,
please visit Teradyne's homepage on the World Wide Web at http://www.teradyne.com.
|